Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | K. J. Lee et al., Exp. Cell Research, 2015, 336: 211-222; doi.org/10.1016/j.yexcr.2015.07.010 | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | M. R. Graf et al., J. of Cancer Ther. & Res., 2012, doi: 10.7243/2049-7962-1-25 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | A. Hermawan et al., Dissertation, 2015, Ludwig-Maximilians-Universität München | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | I. H. Polat et al., Biology, 2021, 10, 85, doi.org/10.3390/biology10020085 | Link | |
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | A. Hermawan, Ludwig-Maximilians-Universität München | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | K2 Transfection System | publication | B. Ljepoja et al.,The Breast, 2019, 43: 31-38, doi.org/10.1016/j.breast.2018.10.007 | Link | ||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | U. K. Mukhopadhyay et al., Cytokine, 2016; 82: 70-79; doi.org/10.1016/j.cyto.2016.01.013 | |||
MCF-7 |
Human breast adenocarcinoma cell line | ATCC HTB-22 | Human | breast | cell line | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | B. Ljepoja et al., PLoS ONE, 2019, 14(11): e0224314, doi.org/10.1371/journal.pone.0224314 | Link | |
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | M. P.V. Shekhar et al., Mol. Cancer Res., Oct 2006; 4: 729 - 745 | Link | ||
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | L. Qin et al., Cell Reports, 2015,13: 2056-2063; doi.org/10.1016/j.celrep.2015.11.015 | Link | ||
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | M. P.V. Shekhar et al., Cancer Res., Mar 2008; 68: 1741 - 1750 | Link | ||
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | H.-K. Lee, PhD Thesis, 2015, Seoul National University | Link | ||
MCF10A |
Human breast fibrocystic disease cell line | ATCC CRL-10317 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | E. Xu et al., Mol. Cancer Res., 2014, 12(3):359-369, DOI: 10.1158/1541-7786.MCR-13-0526 | Link | ||
MCF10A-Rad6B |
Human breast fibrocystic disease cell line, stably expressing Rad6B | Human | breast | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | M. P.V. Shekhar et al., Cancer Res., Mar 2008; 68: 1741 - 1750 | Link | ||
MCF7 |
Human breast fibrocystic disease cell line | ATCC HTB-22 | Human | breast | cell line | adherent | plasmid | stable transfection | K2 Transfection System | publication | B. Ljepoja, Dissertation, 2019, Ludwig-Maximilians-Universität München | Link | |
MDA-MB-157 |
Human breast carcinoma cell line | ATCC HTB-24 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | V. Vella et al., Oncotarget, 2017, 8 (26): 43248-43270 | Link | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | plasmid | stable transfection | Metafectene | publication | Y. Radestock et al., Ann. N.Y. Acad Sci. 1041:462-469 (2005). Doi: 10.1196/annals.1282.070 | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | H.-K. Lee, PhD Thesis, 2015, Seoul National University | Link | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | K. Wang et al., J. Biochem. Mol. Toxicol., 2018, e22039, doi.org/10.1002/jbt.22039 | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | plasmid | Metafectene PRO | publication | A. Ray et al., Mol. Cancer Res., Aug 2011; 9: 1030 - 1041 | Link | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | B. von Neubeck et al., Int. J. of Cancer, 2018, 143: 2065–2075, DOI: 10.1002/ijc.31607 | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | D. Konina et al., Int. J. Mol. Sci., 2021, 22, 8477, doi.org/10.3390/ijms22168477 | Link | |
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | siRNA | cotransfection (plasmid/siRNA) | Metafectene PRO | publication | S. Liu et al., J. Biol. Chem., 2015, 290(29): 17894-17908; DOI 10.1074/jbc.M114.607184 | Link | |
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | plasmid | Metafectene | publication | M. P.V. Shekhar et al., Mol. Cancer Res., Oct 2006; 4: 729 - 745 | Link | ||
MDA-MB-231 |
Human breast adenocarcinoma cell line | ATCC HTB-26 | Human | breast | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M. M. Endres, Dissertation, 2016, Julius-Maximilians-Universität Würzburg |